Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
Open Access
- 15 March 2016
- journal article
- review article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (1), 15
- https://doi.org/10.1186/s40425-016-0118-0
Abstract
The efficacy of PD-1/PD-L1 targeted therapies in addition to anti-CTLA-4 solidifies immunotherapy as a modality to add to the anticancer arsenal. Despite raising the bar of clinical efficacy, immunologically targeted agents raise new challenges to conventional drug development paradigms by highlighting the limited relevance of assessing standard pharmacokinetics (PK) and pharmacodynamics (PD). Specifically, systemic and intratumoral immune effects have not consistently correlated with standard relationships between systemic dose, toxicity, and efficacy for cytotoxic therapies. Hence, PK and PD paradigms remain inadequate to guide the selection of doses and schedules, both starting and recommended Phase 2 for immunotherapies. The promise of harnessing the immune response against cancer must also be considered in light of unique and potentially serious toxicities. Refining immune endpoints to better inform clinical trial design represents a high priority challenge. The Cancer Immunotherapy Trials Network investigators review the immunodynamic effects of specific classes of immunotherapeutic agents to focus immune assessment modalities and sites, both systemic and importantly intratumoral, which are critical to the success of the rapidly growing field of immuno-oncology.This publication has 115 references indexed in Scilit:
- Standardizing immunophenotyping for the Human Immunology ProjectNature Reviews Immunology, 2012
- Cancer immunology—analysis of host and tumor factors for personalized medicineNature Reviews Clinical Oncology, 2011
- Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironmentCurrent Opinion in Immunology, 2011
- Immune parameters affecting the efficacy of chemotherapeutic regimensNature Reviews Clinical Oncology, 2011
- A model for harmonizing flow cytometry in clinical trialsNature Immunology, 2010
- Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use settingCancer, 2010
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerCancer Immunology, Immunotherapy, 2009
- Immunogenic and tolerogenic cell deathNature Reviews Immunology, 2009
- Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell deathThe EMBO Journal, 2009
- Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI projectNature Biotechnology, 2008